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Resistance is futile: overcoming resistance to targeted therapies
in lung adenocarcinoma
Dana S. Neel1,2,3 and Trever G. Bivona1,2,3
The advent of genomics has led to the identification of specific “driver” mutations in oncogenic kinases, and the development of
targeted small molecule inhibitors to block their tumor-driving functions. These specific inhibitors have been a clinical success, and
often significantly prolong the lives of individuals with cancer. Inevitably, however, the treated tumors recur as resistance to these
targeted therapies develops. Here, we review the major mechanisms by which a cancer cell can evade targeted therapy, focusing
on mechanisms of resistance to kinase inhibitors in lung cancer. We discuss the promising concept of rational upfront polytherapy
in lung cancer, which involves concurrently targeting multiple proteins in critical signaling pathways in a cancer cell to prevent or
delay resistance.
npj Precision Oncology  (2017) 1:3 ; doi:10.1038/s41698-017-0007-0
TARGETING DRIVER ONCOGENES IN LUNG ADENOCARCINOMA
A significant fraction of lung adenocarcinomas harbor activating-
mutations in targetable oncogenes. These include mutations in
EGFR (~11%) and BRAF (~7%), and activating gene rearrangements
involving ALK and ROS1 (1–2%), all of which encode protein
kinases, and result in hyperactivation of downstream signaling
pathways that drive cell growth, proliferation, and survival.
The identification of these driver kinases has led to the clinical
use of small molecule kinase inhibitors that suppress these
oncoproteins—erlotinib, gefinitib, afatinib, osimertinib for mutant
EGFR, vemurafenib and dabrafenib for mutant BRAF, and
crizotinib, ceritinib, alectinib for ALK and/or ROS1 gene rearrange-
ments.1–10 These targeted drugs function as ATP-competitive
inhibitors. Additionally, inhibitors of kinases that are activated
downstream of these oncoproteins have been developed for use
as either monotherapy, or in combination with inhibitors of the
upstream oncoprotein. The MEK1/2 inhibitor trametinib is one
such drug—it inhibits MAPK pathway activation by binding to and
blocking MEK in an allosteric fashion. All of these inhibitors have
shown efficacy over conventional chemotherapies in patients
harboring the cognate genetic driver kinase.
MECHANISMS OF RESISTANCE TO TARGETED THERAPIES
Unfortunately, the initial clinical response to targeted kinase
inhibitors is almost always temporary, as acquired resistance to
these drugs invariably develops. Many mechanisms of resistance
to each targeted therapy have been identified, but can be
generally categorized into three predominant classes (Fig. 1): (1)
those that alter the driver oncogene, (2) those that activate a
critical signaling pathway(s) in a parallel or downstream fashion,
and (3) those that drive pro-survival signaling through a different
signaling pathway. A fourth class of resistance encompasses
histological transformation from one cell lineage such as epithelial
to another such as neuroendocrine or mesenchymal. This last class
is generally poorly understood.
Alteration of the driver oncogene
Gatekeeper mutations and other “on-target” mechanisms of
resistance. Small molecule kinase inhibitors bind to their target
through non-covalent bonds within the ATP-binding pocket.
Cancer cells can develop resistance to specific small molecule
kinase inhibitors by mutating a so-called “gatekeeper” residue
within the pocket. This residue is often small in the native
oncoprotein with the secondary resistance-associated mutation
resulting in a bulky amino acid substitution. How gatekeeper
mutations cause resistance to small molecule inhibitors remains
incompletely understood. Initial studies showed that the gate-
keeper mutation both creates a residue that cannot a hydrogen
bond with the inhibitor, and sterically hinders inhibitor binding in
the pocket, while leaving the pocket’s ATP-binding affinity
unchanged.11 The effect of the gatekeeper amino acid substitu-
tion is to prevent kinase-inhibitor binding while allowing retention
of the ability of the kinase to bind ATP. More recently, data
demonstrating that gatekeeper mutants can retain sensitivity to
structurally similar but irreversible inhibitors suggest that steric
hindrance may not explain the gatekeeper mechanism of
resistance in all cases, and instead that the function of a
gatekeeper mutation could be to bind ATP more strongly to
decrease the ability of the ATP-competitive kinase inhibitor to
bind in the pocket.12 Which of these mechanisms is responsible
for gatekeeper mutation-mediated inhibitor resistance may
depend on the kinase in question.
The gatekeeper T790M mutation in EGFR is found in ~50% of
EGFR-mutant patients who develop resistance to EGFR inhibi-
tion.13, 14 Gatekeeper mutations have similarly been identified in
cancers that become resistant to ALK inhibitors (L1196M).
Additionally, other “on-target” mutations in EGFR and ALK have
been described, which are found at other residues within the
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ATP-binding domain and cause targeted inhibitor resistance.15–17
While the gatekeeper threonine mutation has been identified as
an in vitro cause of BRAF inhibitor resistance, this mutation has
not been seen in patients.18 This may be because many BRAF
inhibitors induce paradoxical activation of wild-type RAF.19 Thus,
upregulation of wild-type RAF or RAS signaling can activate the
same pathways that are downstream of mutant BRAF. These
signaling events may obviate the selective pressure to acquire
resistance to so called “paradox activating” RAF inhibitors by
mutation of the driver oncogene itself.
The prevalence of on-target mutations as a mechanism of
resistance has led to the creation of new inhibitors that can inhibit
both the original oncoprotein and its resistance-associated
mutated form. While this strategy does improve patient survival
in the short term, mechanisms of resistance emerge to these
inhibitors as well.4, 20
Other alterations in the driver oncogene can lead to resistance
as well. Studying BRAFV600E mutant lung adenocarcinoma, our
group identified that a switch from expression of a full-length
BRAFV600E to a shorter splice variant was capable of mediating
resistance to the BRAF inhibitor vemurafenib.21 This splice variant
is able to dimerize and activate downstream MAPK pathway
signaling despite presence of the RAF inhibitor. This mechanism of
resistance was observed initially in BRAF-mutant melanomas,
indicating conservation across different tumor histologies.22
Finally, changes in the level of the targeted driver oncogene can
also cause inhibitor resistance. By increasing the levels of the
driver oncogene, an inhibitor appears to be less potent, because
there will be fewer molecules of inhibitor per molecule of
oncoprotein. Upregulation of BRAFV600E was identified as a driver
of resistance in inhibitor-insensitive melanomas.23 Intriguingly,
loss of the initial driver oncogene and replacement with a new
driver, also known as “oncogene swap”, has recently been
described as a cause of targeted inhibitor resistance.24 In this
instance, a cancer cell loses the targeted driver oncogene, and
upregulates a new oncogene, such that oncogenic signaling
driving cell survival is mediated by the new oncogene, and the
inhibitor of the initial oncogene no longer has a substantial impact
on cancer cell survival.
Reactivation of critical signaling pathways
Parallel activation of signaling pathways. One way that cancer
cells can evolve resistance to a targeted therapy without altering
the target oncogene is by upregulating expression and/or
activation of a protein that signals through the same signaling
pathway. In this way, despite continued suppression of the initial
driver oncoprotein by the small molecule inhibitor, critical parallel
signaling persists under the control of the newly upregulated
protein activity.
Amplification of wildtype MET in the setting of EGFR mutant
lung cancer was one of the earliest examples of this type of
mechanism of resistance.25–27 Mutant EGFR heterodimerizes with
ErbB-3 to activate the PI3K/Akt signaling pathway. Upon inhibition
of EGFR with a targeted inhibitor, this pathway is suppressed. MET
amplification leads to the reactivation of this pathway by forming
a MET-ErbB-3 heterodimer.28 Thus, despite continuous suppres-
sion of EGFR by the inhibitor, a critical downstream signaling
pathway is reactivated, and resistance to the inhibitor emerges.
Upregulated expression of the MET ligand HGF, leading to
hyperactivation of MET, has been found to drive resistance to
EGFR inhibition through a similar mechanism as MET amplifica-
tion.29, 30 Clinical trials are underway to test the effect of dual
inhibition of MET and EGFR to overcome this mode of resistance.31
Fig. 1 Mechanisms of resistance to targeted therapies. a. Example of a drug-sensitive tumor. Downstream signaling is decreased upon
addition of a targeted inhibitor. b–e. Examples of mechanisms promoting drug-resistant tumors. b. On-target mutations block the ability of
the drug to bind to and inhibit the target oncoprotein, allowing continued signaling to promote tumor survival. c. Upregulation of a distinct
receptor tyrosine kinase sustains signaling through a critical signaling pathway despite continued inhibition of the primary oncoprotein with
the targeted drug. d. Mutational activation of a protein involved in a critical downstream signaling pathway reactivates the pathway below the
level of inhibitor blockade. e. Activation of pro-survival signaling networks can prevent inhibitor-mediated apoptosis
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Additionally, ErbB-3 blocking antibodies are currently under
clinical development.32 Amplification of the ERBB family member
HER2 has also been identified as a possible mechanism of
resistance to EGFR inhibitors by similarly activating ErbB3 and
downstream PI3K signaling.33 Inhibition of this key signaling
pathway downstream of the activation node is another way to
overcome resistance.34
Upregulation or activation of non-ERBB family member receptor
tyrosine kinases to reactivate downstream signaling pathways,
and cause resistance has also been identified. IGF-1R pathway
activation can mediate resistance in both EGFR-mutant and EML4-
ALK positive lung cancer.35–37 Overexpression of the tyrosine
kinase AXL, which is able to engage multiple downstream
signaling nodes also activated by EGFR, was identified by our
group and others as a driver of EGFR inhibitor resistance.38 Similar
findings were observed in ALK gene rearrangement positive lung
adenocarcinoma.39
Similarly, resistance to Raf inhibition can result from upregu-
lated levels of EGF, which activates EGFR, and drives downstream
pathway activation in BRAFV600E mutant lung adenocarcinoma.21
Combinatorial inhibition of multiple kinases could be a therapeu-
tic possibility in cases where activation of alternative receptor
tyrosine kinases is responsible for driving resistance.
Downstream activation of signaling pathways. Cancer cells can
become resistant to targeted inhibitors by amplifying or acquiring
activating mutations in pathway genes downstream of the driver
oncogene. Thus, despite continued silencing of an oncoprotein’s
activity by its inhibitor, there is persistent pathway activation
downstream of the reactivated pathway node.
Activating mutations in or amplification of genes involved in
MAP kinase pathway signaling have been identified as a
mechanism of resistance to targeted inhibitors of several driver
oncogenes. BRAF mutations drive resistance to targeted inhibition
of EGFR, while KRAS amplification leads to ALK kinase inhibitor
resistance in EML4-ALK-drive lung cancer.40, 41 Similarly, down-
regulation of genes that negatively regulate the MAP kinase
pathway have also been implicated in resistance. Decreased
expression of the phosphatase DUSP6 leading to rescue of
phospho-ERK and reactivation of MAPK signaling was observed
in ALK inhibitor-resistant cell lines and patient samples.40 Similarly,
downregulation of NF1, leading to reduced levels of the Ras-
GTPase activating protein neurofibromin, and thus increased Ras
activity, has been identified as a driver of resistance to EGFR
inhibition in lung cancer.42
Along with signaling through MAPK, the PI3K pathway is
another major signaling pathway that is commonly hyperactivated
downstream of driver oncogenes. Several lines of evidence
suggest that downstream reactivation of this pathway may be a
mechanism of acquired resistance to targeted inhibitors. First,
concurrent EGFR and PIK3CA mutations are seen in patients with
acquired resistance to EGFR inhibition, and are correlated with a
poor response to EGFR-targeted therapy; furthermore, PIK3CA
mutants can drive resistance to EGFR inhibitor in vitro.43, 44 These
mutations lead to increased phosphorylation of PIP2, generating
the second messenger PIP3 and activating AKT. Similarly,
homozygous loss of PTEN, which normally acts to dephosphor-
ylate PIP3 and suppress this signaling pathway, has also been
identified as a mechanism of EGFR inhibitor resistance in vitro in
lung and other cancers.45, 46 However, the clinical significance of
these mutations with regard to inhibitor sensitivity remains
controversial. While concurrent mutations in the PI3K pathway
with EGFR and KRAS mutations are associated with a poorer
prognosis overall, PI3K mutations do not alter sensitivity or clinical
responses to targeted inhibitors in EGFR-mutant lung cancer,
suggesting reactivation of this pathway may not actually be a
cause of targeted inhibitor resistance in patients.47
Alternative pathway activation
Activation of pro-survival signaling pathways. Besides reactivation
of critical pro-growth pathways downstream of a driver oncogene,
activation of pro-survival signaling networks has also been
implicated in targeted inhibitor resistance. Our group discovered
that, upon inhibition of EGFR, an NFκB-containing complex is
rapidly recruited, and activates a downstream pro-survival
signaling pathway that limits EGFR inhibitor-mediated cell
death.48, 49 Co-treatment of cells with EGFR and NFκB inhibitors
prevents the emergence of this resistance in pre-clinical models.49
Activation of pro-survival genes also limits response to MAPK
pathway inhibitors in BRAF and RAS-driven tumors. Our group and
others identified the YAP pathway as a key mediator of response
to MAPK pathway inhibition in these tumors.50–52 In some tumors,
YAP levels are elevated and drive transcription of downstream
targets, including BCL2L1, which encodes the anti-apoptotic BCL-
xL protein. These tumors are more resistant to MAPK pathway
inhibitors because, even without pro-survival MAPK pathway
signaling, these tumors maintain activation of alternative pro-
survival signaling pathways through YAP activation.
These mechanisms of resistance are distinct from those
discussed earlier, as they involve engagement of pathways
separate from those activated by the driver oncogene prior to
inhibitor treatment. In both cases described here, combined
inhibition of the driving oncogenic pathway and the resistance-
mediating pro-survival pathway is an effective way to overcome
targeted inhibitor resistance.49, 50
Additional mechanisms of resistance
Epigenetically regulated drug tolerance. Global epigenetic
changes have been observed in response to small molecule
inhibitor treatment. Sharma and colleagues found that the H3K4
histone demethylase KDM5A was upregulated in inhibitor-
resistant EGFR-mutant cells, and this overexpression was required
for drug resistance.53 Intriguingly, IGF-1R signaling was found to
be required for establishment of this drug-resistant cell popula-
tion, and KDM5A upregulation was linked to IGF-1R signaling. This
finding suggests that upregulation of IGF-1R could contribute to
inhibitor resistance through multiple mechanisms, both by
reactivating critical signaling pathways (as discussed earlier) and
by altering a cell’s epigenetic landscape.
Germline disruption of apoptosis. Germline polymorphisms in
pro-survival signaling pathways have also been implicated in
targeted inhibitor resistance. Ng and colleagues identified a
common polymorphism in BIM, a pro-apoptotic protein, as a
mediator of intrinsic targeted inhibitor resistance in EGFR-driven
lung cancer and chronic myeloid leukemia.54 Normally, MAP
kinase pathway signaling activated by the driver oncogene
suppresses BIM and it’s pro-apoptotic function. Upon treatment
with a targeted inhibitor, this suppression is released, restoring the
pro-death function of BIM. However, some patients harbor a
polymorphism in BIM that lacks the critical pro-apoptotic BH3
domain, thus rendering BIM ineffective in driving apoptosis upon
oncogene inhibition and causing intrinsic resistance to the
targeted inhibitor. In these cases, Ng et al. suggest BH3 mimetics
in combination with targeted oncogene inhibition may be
efficacious in combating intrinsic resistance.
Upregulation of drug transporters. One non-specific mechanism
of small molecule inhibitor resistance is upregulation of drug
efflux pumps. Expression of these pumps has long been
associated with resistance to a variety of cytotoxic cancer
therapies, as they reduce intracellular drug concentration. Some
small molecule tyrosine kinase inhibitors are targets of efflux
pumps, and in some cases, expression of specific drug
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transporters have been reported to induce drug resistance to
targeted inhibitors of EGFR and ALK.55, 56
Epithelial-to-mesenchymal transition (EMT). The EMT has been
observed in association with acquired resistance to targeted
inhibitors in a variety of oncogene-driven cancers, including EML4-
ALK and EGFR mutant lung adenocarcinoma.38 EMT is observed as
a morphologic change in cells, decreased epithelial markers (like
E-cadherin) and upregulated mesenchymal markers (like vimen-
tin), as well as increased migration and invasion properties of cells.
However, whether EMT is directly responsible for acquired
resistance or is an associated but not causal change remains
controversial. For example, induction of EMT by TGFB signaling is
associated with ALK inhibitor resistance in an EML4-ALK-positive
cell line, and knockdown of the mesenchymal marker vimentin
restores sensitivity in an EML4-ALK-acquired resistance model that
displays EMT.57 However, other groups have found that reversal of
the EMT phenotype in ALK inhibitor-resistant EML4-ALK lines can
be induced despite continued resistance to the targeted
inhibitor.58 Thus, whether or not EMT is a driver of resistance or
just a consequence associated with the functional resistance
mechanism remains to be elucidated.
Transformation to small cell carcinoma. Finally, histologic trans-
formation of non-small cell lung adenocarcinoma to small cell
carcinoma is occasionally observed as a mechanism of resistance
to multiple driver oncogene-targeted therapies, including inhibi-
tors of EGFR and EML4-ALK.59–61 Interestingly, these tumors retain
expression of the original mutant oncogene, and do not appear to
have acquired any of the resistance mechanisms discussed above.
Analysis of these small-cell-transformed tumors revealed loss of
RB1, a hallmark of small cell lung cancer.62, 63 Loss of RB1 may be
the alteration that induces this non-small-cell to small-cell
transformation, resulting in a molecular switch from dependence
on the original driver oncogene to a different survival program
regulated by RB1 loss.64
Emergence of resistance
Most patients will have an incomplete response to a given
targeted therapy—that is, their tumors will not completely
regress, and they will have some degree of residual disease from
which acquired resistance subsequently emerges.10 While much
research over the past decade has focused on identifying
mechanisms mediating acquired resistance to targeted inhibitors,
there is still much to be learned about what other factors might be
involved in preventing an initial complete response and support-
ing residual disease. This population of tumor cells that never
completely responds to therapy likely functions as a transition
state culminating eventually in a drug-resistant tumor (acquired
resistance). Therefore, understanding the mechanisms involved in
the survival of this subpopulation of residual tumor cells is critical
for progress.
How resistance emerges in a tumor remains unclear. One
possibility is that certain resistance mechanisms exist in a subset
of tumor cells prior to treatment with a targeted agent. These pre-
existing resistant cells are then selected for upon introduction of
the targeted inhibitor. Many tumors show a great amount of
intratumoral heterogeneity prior to therapy, and there is evidence
of the existence of tumor cells harboring resistance mutations
prior to the treatment with targeted inhibitors.65–68 Another
possibility is that the treatment of tumor cells with a targeted
inhibitor induces a drug-tolerant population of cells from which
resistance can then emerge based on the stochastic presence of
genetic variation due to the underlying mutation rate in
replicating cells.53, 68 A third hypothesis is that targeted inhibition
of an oncogene itself somehow induces epigenetic or genetic
changes, leading to resistance. Likely, any or all modes of
resistance emergence may occur in an individual patient,
depending on the intratumoral heterogeneity present prior to
treatment and the characteristics of the cancer type and inhibitor
used. However, if critical signaling pathways can be predicted and
targeted in a patient in an upfront manner, the emergence of
resistance through either mechanism described here may be
delayed or prevented entirely, offering a promising approach to
combat the heterogeneity and adaptiveness of most cancers.
DEVELOPMENT OF RATIONAL UPFRONT POLYTHERAPY
STRATEGIES
Despite initial frustrations over the inevitable emergence of
resistance to targeted kinase inhibitors, new insights into under-
standing these mechanisms of resistance provide hope for the
development of more durably effective treatment strategies. The
emergence of resistance can suggest which pathway(s) are critical
for the survival of cells driven by specific oncoproteins, suggesting
the potential of upfront combinatorial inhibition of the driver
oncoprotein and the crucial pathway further downstream.
Preclinical studies from our group have demonstrated that upfront
treatment of EML4-ALK positive lung tumors with both an ALK
inhibitor and a MAPK pathway inhibitor can significantly delay or
even prevent onset of resistance.40 The development of clinical
trials to test this upfront therapy in patients is underway. Similar
findings were observed in EGFR mutant lung adenocarcinoma
preclinical models and individuals with BRAF V600E lung
adenocarcinoma.69, 70
So far in this review, we have covered the myriad ways a cancer
cell can develop resistance to targeted therapies. But how can the
knowledge of how cancer cells evade inhibitors translate into real
benefits for patients? Now that many pathways of resistance have
been identified, these specific resistance mechanisms can be
monitored for in the patient once they start inhibitor treatment. In
many cases, additional drugs are available that can be combined
with the initial inhibitor to overcome emerging resistance. The fact
that tumor cells shed their DNA, which can be detected in the
blood of patients, has recently begun to be harnessed to
effectively obtain serial biopsies of a patient’s disease over the
course of treatment. In this way, physicians can easily monitor for
the emergence of genetic alterations associated with resistance to
inhibitors, and potentially deploy combination therapies to short-
circuit the emergence of resistance before it is fully established in
the patient.71, 72 Early pre-clinical and clinical data suggest it may
be critical to combat resistance by treating it before it truly
emerges—once a tumor has recurred on a macroscopic level, it
appears to be less sensitive to inhibitors targeting its resistance
mechanism as when a tumor is initially co-treated with inhibitors
targeting both its driver oncogene and a common resistance
mechanism.73, 74 This clinical experience exemplifies the impor-
tance of early low-level detection of residual disease and tumor
recurrence using liquid biopsies (and where feasible on-treatment
tumor biopsies) so resistance can be addressed prior to the
appearance of macroscopic disease, and of understanding the
signaling pathways that are most critical to tumor survival to allow
for upfront polytherapy to prevent resistance from ever
appearing.10
While this review mostly focuses on resistance to targeted
therapies in lung cancer, the mechanisms can be broadly
applicable to other tumor types as well. First, many other tumors
that harbor the same driver oncogenes discussed here, are
targetable with the same small molecule inhibitors, and show
similar patterns of resistance mechanisms. Second, identification
of resistance mechanisms that may emerge, and then upfront
treatment of patients with combinations of inhibitors to delay or
prevent this resistance from occurring is a concept that is
generalizable to virtually any tumor type. Better understanding
of how the tumor cells escape from the detrimental effects of
Overcoming resistance to therapies in lung adenocarcinoma
DS Neel and TG Bivona
4
npj Precision Oncology (2017)  3 Published in partnership with The Hormel Institute, University of Minnesota
targeted therapies holds promise for our ability to prioritize, and
deploy synergistic drug combinations that chronically control and
potentially eliminate the ability of the tumor to evolve full
resistance. While drug combinations may show clinical toxicity,
prioritizing combinations of agents with synergistic anti-tumor
effects could offer a therapeutic window. Alternatively, sequential
or alternating drug schedules could be tested, where appropriate,
to mitigate clinical toxicity and maintain anti-tumor efficacy.
Altogether, the path to chronic cancer control is clearer and
brighter due to the increasing understanding of the biological
basis of resistance, and the arrival and adoption of emerging
technologies that allow us to chart the molecular course of cancer
evolution in individual patients during treatment.
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